• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » TCT 2014 Roundup

TCT 2014 Roundup

September 16, 2014 By Brad Perriello

TCT 2014 Roundup

Here’s a look at some of the news coming out of Washington at the 26th annual Transcatheter Cardiovascular Therapies conference this week:

 Abbott’s Absorb stent as good as Xience, maybe better for angina
One-year data on the Absorb stent made by Abbott (NYSE:ABT) shows that the bioresorbable device is the equal of its forebear, the drug-eluting Xience stent, and might be better at reducing angina in patients with coronary artery disease.

The study revealed no major difference in the endpoint of all death, all heart attacks and all revascularization (7.3% for Absorb and 9.1% for Xience) or for the endpoint of target lesion failure (4.8% for Absorb and 3.0% for Xience). Patients in the Absorb cohort also showed a 16.4% rate of reported angina, compared with 25.6% for the Xience arm.

Abbott also announced the launch of its Absorb IV trial examining whether Absorb ) is more cost-effective and delivers higher quality of life than a metallic drug eluting stent.
Read more

 St. Jude Medical launches latest Optis platform

St. Jude Medical (NYSE:STJ) said it won CE Mark approval in the European Union and 510(k) clearance from the FDA for the latest version of its Optis platform, designed to integrate optical coherence tomography and fractional flow reserve technology into the workflow for percutaneous coronary interventions.
Read more

 Less time on DAPT as safe as longer courses

Treatment with dual anti-platelet therapy for a shorter duration is as safe as longer courses of DAPT, according to a pair of studies presented at TCT. The Security trial showed that DAPT for 6 months offered as much protection from death, heart attack, stroke, stent thrombosis or bleeding as 12 months on the drugs, Dr. Antonio Colombo of the San Raffaele Scientific Institute in Milan. A 2nd study, the Optimize trial, showed that 3 months of DAPT matches the 12-month standard out to 2 years, as reported by Dr. Fausto Feres of the Instituto Dante Pazzanese de Cardiologia in Sao Paolo.
Read more

 Stents better than DEBs at treating failed stents

A 2nd drug-eluting stent is superior to drug-eluting balloons in treating in-stent restenosis, according to Ribs IV trial
data presented by Dr. Fernando Alfonso of the Hospital Universitario de La Princesa in Madrid.
Read more

 St. Jude Medical reveals positive EnligHTN-III data at 1 year

St. Jude’s EnligHTN renal denervation device showed an average office-measured systolic blood pressure reduction of 23mmHG at 12 months and an average
ambulatory reduction of 10mmHG, with 78% of patients responding to the therapy with at least a 10mmHG reduction.
Read more

Filed Under: News Well, Pharmaceutical, Stents Tagged With: Abbott, Hypertension, stjudemedical, TCT 2014, Trade Show

More recent news

  • Comphya raises CHF 7.5 million for neurostim to treat ED
  • Fujifilm launches intelligent automation features for digital radiography
  • Integer appoints former iRhythm CEO to board
  • MMI debuts robotic surgery instruments, digital surgery platform
  • Synchrony Medical wins FDA nod for airway clearance system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy